MedicineOncologyPharmacologyMolecular OncologyOncogenesSignal TransductionBladder CancerCancer Cell SignalingMalignant NeoplasmsOncogenic Signaling PathwaysRas Family OncogenesSignal Transduction In CancerAnticancer Drug ResistanceMek SignalingMolecular Drug ResistanceOncogenic Ras SignalingProtein Kinase InhibitorsRaf-mek-erk SignalingRas SignalingRas Signaling Pathway
Among eight human bladder cancer cell lines we examined, only T24 cells were resistant to the growth inhibition effect of genistein, an isoflavone and potent anticancer drug. Since the T24 cell line was the only cell line known to overexpress oncogenic H-Ras(val 12), we investigated the role of H-Ras(val 12) in mediating drug resistance. Herein, we demonstrate that the phenotype of T24 cells could be dramatically reversed and became relatively susceptible to growth inhibition by genistein if the synthesis of H-Ras(val 12) or its downstream effector c-Fos had been suppressed. The inhibition of Ras-mediated signalling with protein kinase inhibitors, such as PD58059 and U0126 which inhibited MEK and ERK, in T24 cells also rendered the identical phenotypic reversion. However, this reversion was not observed when an inhibitor was used to suppress the protein phosphorylation function of PI3 K or PKC. These results suggest that the signal mediated by H-Ras(val 12) is predominantly responsible for the resistance of the cells to the anticancer drug genistein.
50
WAF1, a potential mediator of p53 tumor suppression
Wafik S. El‐Deiry, Takashi Tokino, Victor E. Velculescu et al. · Cell · 1993 · 8.4K citations
Genistein, a specific inhibitor of tyrosine-specific protein kinases.
Tetsu Akiyama, Junko Ishida, Shizue Nakagawa et al. · Journal of Biological Chemistry · 1987 · 3.7K citations · Full text
Mechanism of activation of a human oncogene
Clifford J. Tabin, Scott M. Bradley, Cornelia I. Bargmann et al. · Nature · 1982 · 1.4K citations